HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker by 조남훈 & 박철근
1Scientific RepoRtS |         (2019) 9:20205  | https://doi.org/10.1038/s41598-019-56657-8
www.nature.com/scientificreports
HoxB13 expression in ductal type 
adenocarcinoma of prostate: 
clinicopathologic characteristics 
and its utility as potential 
diagnostic marker
Cheol Keun park  1,2, Su-Jin Shin  3, Yoon Ah cho1,4, Jin Woo Joo1 & Nam Hoon cho1*
The histologic criteria and selective biomarkers of prostate ductal type adenocarcinoma (DAC) are 
relatively unknown compared to that known about acinar type adenocarcinoma (AAC). It is known 
that genetic alteration in Hox13 gene is associated with carcinogenesis of prostate cancer. In this 
study, we investigated clinicopathologic characteristics of HoxB13 expression in prostate cancer and 
compared clinicopathologic profiles of DAC and AAC of prostate. After slide review, some morphological 
variants of DAC, equivalent to Gleason pattern 3 and 5 of AAC were identified. High level of HoxB13 
expression was identified in 46.5% (46 out of 99 cases) and 39.2% (31 out of 79 cases) of cases that 
belong to the training set and test set, respectively. In the training set, high level of HoxB13 expression 
was significantly correlated with DAC (P < 0.001), higher Gleason score (P < 0.001), advanced 
pathologic T stage (P = 0.010), and occurrence of biochemical recurrence (BCR; P < 0.001). The test set 
confirmed that high level of HoxB13 expression was associated with DAC (P < 0.001), higher Gleason 
score (P = 0.001), advanced pathologic T stage (P < 0.001), and occurrence of BCR (P < 0.001). Our 
findings suggest that HoxB13 may be a useful diagnostic marker for detection of DAC and a prognostic 
marker for prediction of BCR.
Prostate cancer is one of the most common cancers in males, especially in developed countries1. The majority of 
prostate cancer is acinar type adenocarcinoma (AAC); however, there are several variants of prostate cancer caus-
ing diagnostic difficulties due to the overlapping features with AAC2. Thus, variant forms are often misdiagnosed 
as AAC when using histology samples, causing difficulties in the histologic evaluation of prostate cancer3.
Ductal type adenocarcinoma (DAC) is another common subtype of prostate adenocarcinoma, and its inci-
dence has been gradually increasing4,5. When compared with AAC, patients with DAC are more often diagnosed 
with an advanced T stage and exhibit greater mortality4,6. Generally, DAC shows papillary architecture lined by 
pseudostratified columnar epithelium with voluminous cytoplasm6,7; however, due to its broad spectrum of mor-
phological presentations, DAC cases are often assigned one of several differential diagnoses: metastatic adenocar-
cinoma from the colorectal area, urothelial carcinoma, high-grade prostatic intraepithelial neoplasia (HGPIN), 
and intraductal prostate cancer (IDC-P)7,8.
A study about interobserver variabilities in the diagnosis of DAC was conducted, and among several diagnos-
tic parameters, papillary architecture was found to be the most useful feature for diagnosis of DAC. Interobserver 
discrepancies, however, still remain a major obstacle in its diagnosis3. To address this problem, several studies 
have been performed to identify diagnostic markers of DAC; although, distinguishing DAC from AAC remains 
difficult9–11.
Hox genes, composed of four paralogous clusters, are located on four different chromosomes12. Among these 
genes, posterior Hox genes, particularly HoxA13, HoxB13, and HoxD13, are important for the development of 
1Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 
2Department of Pathology, Armed Forces Capital Hospital, Seongnam, Republic of Korea. 3Department of Pathology, 
Hanyang University College of Medicine, Seoul, Republic of Korea. 4Department of Pathology and Translational 
genomics, Samsung medical center, Seoul, Republic of Korea. *email: cho1988@yuhs.ac
open
2Scientific RepoRtS |         (2019) 9:20205  | https://doi.org/10.1038/s41598-019-56657-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
the separate lobes of the prostate gland, seminal vesicles, and epididymis. In addition, each Hox13 gene is asso-
ciated with a lobe-specific prostatic identity and cellular differentiation13,14. Genetic alteration of HoxA13 and 
HoxB13 genes is associated with the development of prostate cancer14–17. Specifically, a germline G84E mutation 
in HoxB13 was associated with hereditary prostate cancer16. Furthermore, dysregulation of HoxB13 has been 
reported in colon, breast, and lung cancers as well as in cutaneous melanoma18–20. Despite these findings, differen-
tial HoxB13 expression according to histologic subtype and the clinical implications of Hox expression in prostate 
cancer have not been fully investigated. Thus, in this study, we evaluated the expression of HoxA13 and HoxB13 
in DAC versus AAC to identify their roles as diagnostic markers for DAC.
Results
Histopathologic reassessment of 178 prostate cancer cases. After the slide review, 25 cases pre-
viously diagnosed as DAC, including 19 equivocal cases, were reclassified as AAC, and 18 cases previously 
diagnosed as AAC were reclassified as DAC. Therefore, 68 cases of DAC and 110 cases of AAC were used for 
comparison of the clinicopathologic characteristics based on the histologic subtypes.
DACs that fulfilled all diagnostic criteria for ductal component were all assigned as Gleason pattern 4. 
The majority of cases arose from the inner zone of periurethral primary ducts with expansile invasive pattern 
(Fig. 1A,B). They showed complex papillary patterns with fibrovascular cores, and the papillary architecture was 
composed of tall columnar tumor cells, mimicking colon or endometrioid adenocarcinoma. Coagulative necrosis 
was rarely identified, unlike in colon or endometrioid type adenocarcinoma. In addition, less pleomorphism and 
stratification were identified compared to those of urothelial carcinoma.
In addition to the Gleason pattern 4 DACs, which fulfilled all diagnostic criteria, 10 cases that had been origi-
nally classified as DAC showed some morphological variants in the juxtaposed: 6 cases with tubular structures, 2 
cases with growth patterns equivalent to Gleason pattern 5 of AAC and 2 cases with both variants. Simple tubular 
structures were composed of tall columnar tumor cells with elongated nuclei and were intermingled with conven-
tional DACs; however, no evidence of papillary cores was observed (Fig. 1C,D). These tubular structures showed 
different morphological features than those of AAC, raising the possibility of DACs with Gleason pattern 3.
Two growth patterns equivalent to Gleason pattern 5 of AAC were observed adjacent to conventional DACs 
(Fig. 2A). Two cases showed central comedo-type necrosis (Fig. 2B). Having a comparatively larger size than 
AAC was a prerequisite for determination of DAC. Infiltrative cord-like patterns that mimicked invasive lobular 
carcinoma of the breast was observed in two cases (Fig. 2C).
Clinicopathologic features of patients. Clinicopathologic analysis was performed on the training set and 
test set, respectively. In the training set, DAC was significantly associated with a higher Gleason score (P < 0.001), 
tumor volume more than 5cc (P = 0.004), presence of extraprostatic extension (EPE; P = 0.004), advanced patho-
logic T stage (P = 0.016), intact PTEN expression (P < 0.001) and occurrence of biochemical recurrence (BCR; 
P = 0.004). The results of clinicopathologic analysis on the test set was similar to that of training set. DAC was 
significantly correlated with a higher Gleason score (P < 0.001), presence of EPE (P < 0.001), advanced pathologic 
Figure 1. Morphological features of representative cases of Gleason pattern 3 DAC. (A,B) The majority of 
DACs shows Gleason pattern 4 and arose from the inner zone of periurethral primary ducts with an expansive 
invasive pattern (marked as “D”). Some tubular structures which is adjacent to Gleason pattern 4 DACs are 
identified (marked with asterisk). (C,D) On the higher magnification of areas marked with asterisk, these 
tubular structures are composed of tall columnar tumor cells with elongated nuclei.
3Scientific RepoRtS |         (2019) 9:20205  | https://doi.org/10.1038/s41598-019-56657-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
T stage (P < 0.001), ERG positivity (P = 0.012) and occurrence of BCR (P = 0.004). The results of chi-square anal-
ysis of the clinicopathologic factors are summarized in Table 1.
Clinicopathologic characteristics according to HoxA13 and HoxB13 expression status. In 
the almost all of cases, HoxA13 and HoxB13 were expressed in the nucleus of tumor cells, with concomitant 
non-specific cytoplasmic staining. HoxA13 is highly expressed in tumor cells of Gleason pattern 4 DACs, espe-
cially those surrounding papillary cores and comprising large ducts (Fig. 3A). In morphological variants of DAC 
and AAC, the expression of HoxA13 is relatively weaker compared to that of Gleason pattern 4 DACs (Fig. 3B). 
For HoxB13, the expression patterns within each tumor subtype and Gleason pattern differed. The expression of 
HoxB13 was similar to that of HoxA13 in Gleason pattern 4 DACs (Fig. 3C). Morphological variants of DAC, 
which is located adjacent to Gleason pattern 4 DACs, also showed expression of HoxB13 in columnar cells of 
Gleason pattern 3 DACs (Fig. 3D) and singly scattered tumor cells or those comprising large nests with central 
comedo-type necrosis of Gleason pattern 5 DACs (Fig. 3E). On the contrary, HoxB13 expression was lower in 
AAC cases compared with DACs (Fig. 3F). All of 19 equivocal cases showed high HoxB13 expression. The valida-
tion results of HoxA13 and HoxB13 antibody are presented in Supplementary Fig. 1.
High HoxB13 expression was identified in 46.5% (46 out of 99 cases) and 39.2% (31 out of 79 cases) of cases 
that belong to the training set and test set, respectively. In the training set, high level of HoxB13 expression 
was significantly associated with DAC (P < 0.001), a higher Gleason score (P < 0.001), tumor volume more than 
5cc (P = 0.042), presence of EPE (P = 0.001), advanced pathologic T stage (P = 0.010), intact PTEN expression 
(P < 0.001) and occurrence of BCR (P < 0.001). The test set showed the results similar to those of the training 
set. High level of HoxB13 expression was significantly correlated with DAC (P < 0.001), a higher Gleason score 
(P = 0.001), presence of EPE (P < 0.001), presence of lymphovascular invasion (LVI; P = 0.001), involvement 
of seminal vesicle (P = 0.043), advanced pathologic T stage (P < 0.001), lower ERG expression (P = 0.016), and 
occurrence of BCR (P < 0.001). In addition, high level of HoxB13 expression showed a tendency toward tumor 
volume more than 5cc (P = 0.056), and frequent intact PTEN expression (P = 0.065). The results of chi-square 
analysis are summarized in Table 2.
High HoxA13 expression was identified in 60.6% (60 out of 99 cases) and 58.2% (46 out of 79 cases) of cases 
that belong to the training set and test set, respectively. In the training set, high level of HoxA13 expression was 
significantly associated with presence of EPE (P = 0.008), and advanced pathologic T stage (P = 0.015). However, 
no significant correlation between high HoxA13 expression and various clinicopathologic factors was identified 
in the test set. The results of chi-square analysis are summarized in Supplementary Table S1, and representative 
immunoprofiles are presented in Supplementary Fig. 2.
Interobserver agreement. Prior to estimating the interobserver agreement, we established two diagnos-
tic criteria for the reproducible assessment of DAC. Morphologic criteria were described in the Materials and 
methods section as a diagnostic criteria for the ductal component. Immunophenotypic criteria were based on the 
Figure 2. Morphological features of representative cases of Gleason pattern 5 DAC. (A) Gleason pattern 4 
DACs (marked as “D”) shows expansile invasive pattern and some morphological variants are identified at the 
periphery of Gleason pattern 4 DACs (marked with asterisk). (B) On the higher magnification of areas marked 
with asterisk, tumor cell nests with central comedo-type necrosis are observed adjacent to the Gleason pattern 
4 DACs. Comparatively larger in size than Gleason pattern 5 of AAC. (C) In other cases, infiltrative cord-like 
patterns mimic invasive lobular carcinoma are noted.
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morphologic criteria and HoxB13 expression. Equivocal cases that exhibited high level of HoxB13 expression were 
classified as DAC.
In the training set, interobserver agreement was 66.7% (63 out of 99 cases), and kappa value was 0.214 [95% 
confidence interval (CI), 0.017–0.418]) without specific diagnostic criteria. However, in the second round, follow-
ing application of the morphologic criteria, the interobserver agreement increased to 69.7% (69 out of 99 cases), 
and the kappa value was 0.353 (95% CI, 0.154–0.539). With the additional application of the immunophenotypic 
criteria, the interobserver agreement further increased to 83.8% (83 out of 99 cases), and the kappa value was 
0.670 (95% CI, 0.515–0.805). In the test set, the interobserver agreement after the application of the morphologic 
criteria was 75.9% (60 out of 79 cases) and kappa value was 0.498 (95% CI, 0.286–0.677). With application of the 
immunophenotypic criteria, the interobserver agreement further increased to 83.5% (66 out of 79 cases), and the 
kappa value was 0.657 (95% CI, 0.476–0.821).
Impact of histologic subtype and HoxB13 expression on BCR-free survival and prognosis. In 
the training set, no significant differences in BCR-free survival between AAC and DAC were observed (P = 0.141; 
Fig. 4A) before the application of our diagnostic criteria. However, after the application of our diagnostic criteria, 
significant difference was identified between the subgroups. When applying morphologic criteria, DAC and AAC 
were found to have significantly different BCR-free survival (P < 0.001; Fig. 4B). When based on immunopheno-
typic criteria, DAC cases had significantly shorter BCR-free survival than AAC cases with low level of HoxB13 
expression, and 13 equivocal cases with high level of HoxB13 expression showed similar BCR-free survival as 
DAC cases (P < 0.001 and P = 0.001, respectively; Fig. 4C).
Survival analysis on the test set validated our diagnostic criteria for DAC. When applying morphologic criteria 
in the test set, DAC and AAC showed significantly different BCR-free survival (P < 0.001; Fig. 4D). When apply-
ing immunophenotypic criteria, DAC cases had significantly shorter BCR-free survival than AAC cases with low 
Category Variables
Training set Test set





(n = 63) P-value





(n = 47) P-value
Age (y) 67.7 ± 7.90 66.0 ± 7.59 0.272 66.3 ± 5.90 65.2 ± 7.79 0.513
Pre-operative PSA 
(ng/mL) 12.8 ± 9.76 11.4 ± 14.5 0.612 11.7 ± 7.46 9.54 ± 6.99 0.179
Gleason score
8 69 17 (47.2) 52 (82.5) <0.001 55 15 (46.9) 40 (85.1)
<0.001
9–10 30 19 (52.8) 11 (17.5) 24 17 (53.1) 7 (14.9)
Location
Unilateral 23 8 (22.2) 15 (23.8) 0.857 14 5 (15.6) 9 (19.1)
0.687
Bilateral 76 28 (77.8) 48 (76.2) 65 27 (84.4) 38 (80.9)
Tumor volume
≤5 cc 74 21 (58.3) 53 (84.1) 0.004 60 21 (65.6) 39 (83.0)
0.076
>5 cc 25 15 (41.7) 10 (15.9) 19 11 (34.4) 8 (17.0)
EPE
Absent 52 12 (38.9) 40 (31.7) 0.004 47 10 (31.3) 37 (78.7)
<0.001
Present 47 24 (61.1) 23 (68.3) 32 22 (68.7) 10 (21.3)
PNI
Absent 7 3 (8.3) 4 (6.3) 0.703 5 3 (9.4) 2 (4.3)
0.390
Present 92 33 (91.7) 59 (93.7) 74 29 (90.6) 45 (95.7)
LVI
Absent 88 31 (86.1) 57 (90.5) 0.522 67 25 (78.1) 42 (89.4)
0.210
Present 11 5 (13.9) 6 (9.5) 12 7 (21.9) 5 (10.6)
RM extension
Absent 34 14 (43.4) 20 (41.7) 0.472 42 18 (56.3) 24 (51.1)
0.650
Present 65 22 (58.6) 43 (58.3) 37 14 (43.7) 23 (48.9)
SV involvement
Absent 82 27 (75.0) 55 (87.3) 0.118 69 25 (78.1) 44 (93.6)
0.081
Present 17 9 (25.0) 8 (12.7) 10 7 (21.9) 3 (6.4)
Pathologic T stage
T2 46 11 (30.6) 35 (55.6) 0.016 47 10 (31.3) 37 (78.7)
<0.001
T3 and T4 53 25 (69.4) 28 (44.4) 32 22 (68.7) 10 (21.3)
Pathologic N stage*
N0 68 32 (88.9) 36 (100.0) 0.115 40 26 (96.3) 14 (100.0)
>0.999
N1 4 4 (11.1) 1 1 (3.7)
PTEN IHC
Intact 55 30 (83.3) 25 (39.7) <0.001 33 10 (31.3) 23 (48.9)
0.118
Loss 44 6 (16.7) 38 (60.3) 46 22 (68.7) 24 (51.1)
ERG IHC
Negative 83 32 (88.9) 51 (81.0) 0.302 60 29 (90.6) 31 (66.0)
0.012
Positive 16 4 (11.1) 12 (19.0) 19 3 (9.4) 16 (34.0)
BCR
Absent 57 14 (38.9) 43 (68.3) 0.004 61 19 (59.4) 42 (89.4)
0.004
Present 42 22 (61.1) 20 (31.7) 18 13 (40.6) 5 (10.6)
Table 1. Clinicopathological characteristics of 178 prostate cancers according to the histologic subtype in 
training set and test set. Abbreviations: DAC, ductal type adenocarcinoma; AAC, acinar type adenocarcinoma; 
PSA, prostate-specific antigen; EPE, extraprostatic extension; PNI, perineural invasion; LVI, lymphovascular 
invasion; RM, resection margin; SV, seminal vesicle; IHC, immunohistochemistry; BCR, biochemical 
recurrence. *Evaluated in 113 prostatectomy specimens.
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level of HoxB13 expression, and 6 equivocal cases with high level of HoxB13 expression showed similar BCR-free 
survival as DAC cases (P < 0.001 and P = 0.003, respectively; Fig. 4E).
Univariate analysis identified the following characteristics that were associated with shorter BCR-free survival: 
DAC (P < 0.001), higher Gleason score (P < 0.001), bilateral location (P = 0.032), tumor volume more than 5 cc 
(P < 0.001), presence of EPE (P < 0.001), presence of LVI (P = 0.001), extension to resection margin (P < 0.001), 
involvement of seminal vesicles and/or lymph node metastasis (P < 0.001), and high level of HoxB13 expres-
sion (P < 0.001). In contrast, loss of PTEN expression (P < 0.001) was associated with longer BCR-free survival. 
Following multivariate analysis, DAC (P = 0.045), extension to the resection margin (P = 0.001) and high level of 
HoxB13 expression (P < 0.001) were associated with shorter BCR-free survival. In contrast, loss of PTEN expres-
sion (P = 0.049) was associated with longer BCR-free survival. The results of univariate and multivariate analyses 
are summarized in Table 3.
Proposed diagnostic algorithm for DAC. Morphologic criteria and immunophenotypic criteria showed 
strong correlation in the training set (Spearman’s correlation coefficient = 0.685, P < 0.001) and the test set 
(Spearman’s correlation coefficient = 0.657, P < 0.001), respectively. In addition, the immunophenotypic criteria 
showed superior interobserver agreement compared to morphologic criteria. Thus, HoxB13 immunohistochem-
istry (IHC) can be used as a diagnostic marker for DAC in cases with uncertain morphologic features. Based on 
these findings, we propose a new diagnostic algorithm for DAC (Fig. 5).
Discussion
Histologic subtypes other than AAC represent less than 10% of all prostate cancer cases21. DAC is usually com-
bined with AAC to yield mixed type adenocarcinomas. According to several studies, the proportion of cases clas-
sified as this mixed type adenocarcinoma varies from 0.13% to 12.7%6,21–23. Although less frequent, the biologic 
behavior of DAC is aggressive, exhibiting frequent EPE, involvement of seminal vesicles, extension to the surgical 
resection margins, presence of LVI, and BCR4,24. Moreover, DAC also metastasizes to unusual sites, such as the 
lung, liver, and brain25.
Despite the high mortality rate of DAC, it is difficult to detect this tumor type because of the frequent subnor-
mal prostate-specific antigen (PSA) levels26. A study about the interobserver variability in the diagnosis of DAC 
was conducted and papillary architecture was proven to be the most important factor for the diagnosis of DAC3. 
However, despite several studies to elucidate the immunoprofile of DAC9–11, definitive diagnostic markers for 
DAC have not yet been identified.
In this study, we evaluated the morphological patterns of DAC and the differences in expression of HoxA13 
and HoxB13 between DAC and AAC. HoxB13 was strongly expressed in Gleason pattern 4 DACs. In addi-
tion, HoxB13 was expressed in tumor cells that exhibited tubular structures or growth patterns equivalent to 
Gleason pattern 5 of AAC. These findings raise the possibility of variable Gleason patterns, including 3 and 5, 
for DACs. DACs with Gleason pattern 3 and 5 were observed in the vicinity of DAC nodules. DACs with tubular 
features (Gleason pattern 3) were more frequently identified than DACs with Gleason pattern 5; however, DACs 
Figure 3. Expression of HoxA13 and HoxB13 in prostate cancer. HoxA13 and HoxB13 is expressed in the 
nuclei with non-specific cytoplasmic staining. (A) In Gleason pattern 4 DACs, HoxA13 is expressed in tumor 
cells, especially those surrounding papillary cores and comprising large ducts. (B) In morphological variants 
of DAC and AAC, HoxA13 expression is weaker compared to that of Gleason pattern 4 DACs. (C) Similar to 
HoxA13, HoxB13 is expressed in tumor cells of Gleason pattern 4 DACs, with especially strong expression in 
cells surrounding papillary cores and comprising large ducts. (D) DACs with a Gleason pattern 3 also showed 
high level of HoxB13 expression. (E) High level of HoxB13 expression is also identified in DACs with a Gleason 
pattern 5. (F) All of the AACs showed low level of HoxB13 expression except for 19 equivocal cases.
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with Gleason pattern 3 formed larger tubular glands than those of AAC and were composed of tall columnar 
amphophilic cells with pseudostratification. DACs having Gleason pattern 5 manifested as central comedo-type 
necrosis or infiltrative cord-like patterns mimicking invasive lobular carcinoma of the breast. These Gleason 
pattern 5 DACs were comparatively larger in size than AACs and intermingled with Gleason pattern 4 DACs. 
However, we did not identify any other variants with a Gleason pattern 5, such as a solid sheet-like growth cor-
responding to that of AAC. Further studies are necessary to investigate the various variants with Gleason pattern 
3 and 5 in DACs.
No significant correlation was identified between HoxA13 expression and histologic subtype by morphologic 
criteria; however, the majority of DAC cases showed high level of HoxB13 expression and were associated with 
intact PTEN protein expression and ERG negativity, consistent with previous study results10. In a previous study, 
Morais et al. suggested the possibility of a clonal relationship between ductal and acinar components of mixed 
type adenocarcinomas10. In addition, the HoxB13 gene regulates luminal differentiation of prostatic epithelium 
in animal models13. Thus, it is plausible to assume that the expression level of the HoxB13 gene is associated with 
the development of DAC. Further studies are required to elucidate the relationship between HoxB13 expression 
and the development of DAC.
We identified a strong correlation between subgroups based on the morphologic and immunophenotypic cri-
teria in the training set and the test set. In addition, interobserver agreement based on the immunophenotypic 
criteria was better than that based on the morphologic criteria in both cohorts. In addition to diagnostic reproduc-
ibility, the changes in diagnostic criteria affected prognostic classification of prostate cancer patients. Before the 
application of morphologic criteria, no significant differences in BCR-free survival were identified between AAC 
and DAC; however, after the application of morphologic criteria, DACs were found to have a shorter BCR-free 
Category Variables
Training set Test set





(n = 53) P-value





(n = 48) P-value
Age (y) 68.2 ± 7.80 65.3 ± 7.45 0.062 65.9 ± 6.66 65.6 ± 7.38 0.871
Pre-operative PSA 
(ng/mL) 11.8 ± 9.05 12.0 ± 15.7 0.934 11.1 ± 7.81 10.0 ± 6.87 0.516
Histologic subtype
AAC 63 13 (28.3) 50 (94.3) <0.001 47 6 (19.4) 41 (85.4) <0.001
DAC 36 33 (71.7) 3 (5.7) 32 25 (80.6) 7 (14.6)
Gleason score
8 69 23 (50.0) 46 (86.8) <0.001 55 15 (48.4) 40 (83.3) 0.001
9–10 30 23 (50.0) 7 (13.2) 24 16 (51.6) 8 (16.7)
Location
Unilateral 23 8 (17.4) 15 (28.3) 0.200 14 7 (22.6) 7 (14.6) 0.363
Bilateral 76 38 (82.6) 38 (71.7) 65 24 (77.4) 41 (85.4)
Tumor volume
 ≤ 5 cc 74 30 (65.2) 44 (83.0) 0.042 60 20 (64.5) 40 (83.3) 0.056
 > 5 cc 25 16 (34.8) 9 (17.0) 19 11 (35.5) 8 (16.7)
EPE
Absent 52 16 (34.8) 36 (67.9) 0.001 47 10 (32.3) 37 (77.1) <0.001
Present 47 30 (65.2) 17 (32.1) 32 21 (67.7) 11 (22.9)
PNI
Absent 7 4 (8.7) 3 (5.7) 0.701 5 3 (9.7) 2 (4.2) 0.376
Present 92 42 (91.3) 50 (94.3) 74 28 (90.3) 46 (95.8)
LVI
Absent 88 40 (87.0) 48 (90.6) 0.569 67 21 (67.7) 46 (95.8) 0.001
Present 11 6 (13.0) 5 (9.4) 12 10 (32.3) 2 (4.2)
RM extension
Absent 34 16 (34.8) 18 (34.0) 0.932 42 17 (54.8) 25 (52.1) 0.811
Present 65 30 (65.2) 35 (66.0) 37 14 (45.2) 23 (47.9)
SV involvement
Absent 82 35 (76.1) 47 (88.7) 0.098 69 24 (77.4) 45 (93.8) 0.043
Present 17 11 (23.9) 6 (11.3) 10 7 (22.6) 3 (6.2)
Pathologic T stage
T2 46 15 (32.6) 31 (58.5) 0.010 47 10 (32.3) 37 (77.1) <0.001
T3 and T4 53 31 (67.4) 22 (41.5) 32 21 (67.7) 11 (22.9)
Pathologic N stage*
N0 68 40 (90.9) 28 (100.0) 0.152 40 23 (100.0) 17 (94.4) 0.439
N1 4 4 (9.1) 1 1 (5.6)
PTEN IHC
Intact 55 36 (78.3) 19 (35.8) <0.001 46 22 (71.0) 24 (50.0) 0.065
Loss 44 10 (21.7) 34 (64.2) 33 9 (29.0) 24 (50.0)
ERG IHC
Negative 83 40 (87.0) 43 (81.1) 0.432 60 28 (90.3) 32 (66.7) 0.016
Positive 16 6 (13.0) 10 (18.9) 19 3 (9.7) 16 (33.3)
BCR
Absent 57 15 (32.6) 42 (79.2) <0.001 61 15 (48.4) 46 (95.8) <0.001
Present 42 31 (67.4) 11 (20.8) 18 16 (51.6) 2 (4.2)
Table 2. Clinicopathological characteristics of 178 prostate cancers HoxB13 expression status in training 
set and test set. Abbreviations: DAC, ductal type adenocarcinoma; AAC, acinar type adenocarcinoma; PSA, 
prostate-specific antigen; EPE, extraprostatic extension; PNI, perineural invasion; LVI, lymphovascular 
invasion; RM, resection margin; SV, seminal vesicle; IHC, immunohistochemistry; BCR, biochemical 
recurrence *Evaluated in 113 prostatectomy specimens.
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survival than AACs. In addition, after application of the immunophenotypic criteria, the equivocal cases with high 
level of HoxB13 expression exhibited BCR-free survival similar to that of DACs. Thus, our findings suggest that 
immunophenotypic criteria could be useful to determine the histologic subtypes of equivocal cases.
Upon univariate and multivariate analysis, the high level of HoxB13 expression was identified as a significant 
factor for the prediction of BCR, which is the similar findings to those of the previous study27. Based on our IHC 
and survival analyses results, we conclude that HoxB13 can be used as a diagnostic marker for DAC. In addition, 
HoxB13 expression can also be used as a prognostic marker, regardless of histologic subtype. Despite these prom-
ising findings, this study has a limitation because it is performed on the single cohort from the single institute. 
Therefore, additional studies using larger and independent cohorts are necessary to validate these conclusions.
In summary, we investigated the morphological features of DAC and the expression of HoxB13 in 178 radical 
prostatectomy (RP) specimens. DACs showed various morphological features that lead to diagnostic difficulties; 
however, using HoxB13 expression analysis for immunophenotypic criteria combined with morphologic charac-
teristics resulted in improved interobserver agreement and prognostic significance. Therefore, we suggest that 
when a final diagnosis remains equivocal, HoxB13 IHC can be an excellent ancillary measure to diagnose DAC.
Materials and Methods
Patient selection and clinical information. All 1460 consecutive RP specimens from 2008 to 2014 were 
selected from the archive of the Severance Hospital. Cases with neoadjuvant androgen deprivation therapy were 
excluded. To rule out the possibility of other conditions, such as HGPIN or IDC-P, that mimic DAC, dual IHC for 
high molecular weight cytokeratin and α-methylacyl-CoA racemase was performed. After evaluation of hema-
toxylin and eosin (H&E)-stained slides and dual IHC, 75 cases, including 15 mixed-type adenocarcinoma cases, 
were eventually selected as the DAC group. As a control group, 103 consecutive RP specimens diagnosed as AAC 
from 2008 to 2014 were included and matched with a corresponding Gleason score of ≥ 8. The entire cases were 
randomly assigned to 99 cases of training set and 79 cases of test set.
Several clinical factors, including age at the time of operation, follow-up level of PSA, and other follow-up data 
were obtained via medical record review. Cases with serum PSA > 0.2 ng/mL at least 6 weeks after surgery and 
a second confirmatory increase thereafter were considered to have BCR. BCR-free time was estimated from the 
Figure 4. BCR-free survival of 178 prostate cancer patients. (A) In the training set, no significant differences in 
BCR-free survival between AAC and DAC were observed (P = 0.141). (B) When applying morphologic criteria, 
DAC and AAC were found to have significantly different BCR-free survival (P < 0.001). (C) When applying 
immunophenotypic criteria, DAC cases showed significantly shorter BCR-free survival than AAC cases with 
low level of HoxB13 expression, and 13 equivocal cases with high level of HoxB13 expression showed similar 
BCR-free survival as DAC cases (P < 0.001 and P = 0.001, respectively). (D) When applying morphologic criteria 
in the test set, DAC and AAC showed significantly different BCR-free survival (P < 0.001). (E) When applying 
immunophenotypic criteria in the test set, DAC cases had significantly shorter BCR-free survival than AAC cases 
with low level of HoxB13 expression, and 6 equivocal cases with high level of HoxB13 expression showed similar 
BCR-free survival as DAC cases (P < 0.001 and P = 0.003, respectively). †Refers to the comparison between 
AACs with low HoxB13 expression and DACs. ‡Refers to the comparison between AACs with low HoxB13 
expression and equivocal cases with high HoxB13 expression.
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date of the first curative surgery to the date of BCR or death without any type of relapse. This study was approved 
by the Institutional Review Board of the Severance Hospital (4-2018-0641) and informed consent were obtained 
from all patients. This study was performed in accordance with the Declaration of Helsinki.
Histopathological evaluation. All cases were reviewed by three independent pathologists via evaluation of 
H&E-stained whole-section slides. Pathologic factors, including Gleason score (based on the 2014 International 
Society of Urological Pathology consensus)28, EPE, LVI, perineural invasion, extension to resection margin, sem-
inal vesicle involvement, and pathologic stage based on the 8th American Joint Committee on Cancer criteria29 
were acquired. Tumor volume was calculated by visual inspection method as previously described30.
For the diagnosis of DAC, we newly defined the following as diagnostic criteria for the ductal component: 
(1) topographical origin of central primary ducts close to urethral lumen, (2) true papillary and/or cribriform 
architecture more than three times larger than typical acini, (3) tall columnar epithelium that was at least three 
times longer than the height of the nuclei and stratified or elongated nuclei with prominent nucleoli. Cases that 
satisfied at least two of diagnostic criteria were classified as DAC. Equivocal cases that satisfied only one criterion 
were considered to be AAC.
IHC and interpretation. The antibodies used for IHC on formalin-fixed paraffin-embedded tissue whole 
sections are shown in Supplementary Table S2. IHC was conducted with the Ventana Discovery XT automated 
stainer (Ventana Medical Systems, Tucson, AZ, USA) according the manufacturer’s protocol. Cell Conditioning 
1 buffer (EDTA, pH 8.0, Ventana Medical Systems) was used for antigen retrieval.
Interpretation of IHC results was performed by a urologic pathologist. Cytoplasmic staining of HoxA13 




HR (95% CI) P-value HR (95% CI) P-value
Age (y)*
≤67 1 —
>67 1.132 (0.703–1.823) 0.610 — —
Histologic subtype
AAC 1 1
DAC 4.127 (2.422–7.032) <0.001 1.907 (1.015–3.585) 0.045
Gleason score
8 1 —
9–10 2.777 (1.721–4.482) <0.001 — —
Location
Unilateral 1 —
Bilateral 2.169 (1.070–4.396) 0.032 — —
Tumor volume
≤5 cc 1 —
>5 cc 3.997 (2.447–6.529) <0.001 — —
EPE
Absent 1 1
Present 2.986 (1.814–4.914) <0.001 0.975 (0.506–1.880) 0.940
Perineural invasion
Absent 1 —
Present 0.729 (0.315–1.687) 0.460 — —
LVI
Absent 1 1
Present 2.707 (1.521–4.817) 0.001 0.882 (0.413–1.882) 0.745
RM extension
Absent 1 1
Present 2.789 (1.608–4.836) <0.001 2.957 (1.546–5.655) 0.001
SVI and/or LNM
Absent 1 1
Present 3.308 (2.008–5.450) <0.001 1.862 (0.977–3.547) 0.059
Pathologic T stage
T2 1 —
T3 and T4 3.098 (1.853–5.177) <0.001 — —
HoxA13 IHC
Low 1 —
High 0.939 (0.562–1.569) 0.810 — —
HoxB13 IHC
Low 1 1
High 6.742 (3.721–12.217) <0.001 4.293 (2.013–9.152) <0.001
PTEN IHC
Loss 1 1
Intact 0.331 (0.182–0.603) <0.001 0.531 (0.282–0.999) 0.049
ERG IHC
Negative 1 —
Positive 0.616 (0.303–1.251) 0.180 — —
Table 3. Univariate and multivariate analysis of BCR-free survival in 178 prostate cancers. Abbreviations: 
DAC, ductal type adenocarcinoma; AAC, acinar type adenocarcinoma; EPE, extraprostatic extension; LVI, 
lymphovascular invasion; RM, resection margin; SVI, seminal vesicle involvement; LNM, lymph node 
metastasis; IHC, immunohistochemistry *Median age of 178 patients was 67.0 y.
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HoxB13 IHC were evaluated using a classification system based on the proportion and intensity of staining, 
as previously described31. The proportion category was assigned as follows: 1 = 0–4%, 2 = 5–19%, 3 = 20–39%, 
4 = 40–59%, 5 = 60–79%, and 6 = 80–100%. Intensity category was assigned as follows: 0 = no staining, 1 = weak, 
2 = intermediate, and 3 = strong. Quickscore was defined as the product of the proportion and intensity scores31. 
Quickscores ≥3 were considered to be high expression, and those <3 were regarded as low expression.
PTEN expression was evaluated by comparing staining between malignant glands and adjacent benign glands 
or stroma. As previously described, cases with markedly decreased or completely negative staining across entire 
tumor glands compared with the adjacent benign glands or stroma were considered to have loss of PTEN expres-
sion10,32. The other cases were considered to have intact PTEN expression. Cases with any tumor cells showing 
nuclear ERG expression were considered positive for expression.
Evaluation of correlation and interobserver agreement. Samples were examined in a double-blind 
manner by two independent experienced pathologists (YA Cho [observer A] and JW Joo [observer B]). Both 
pathologists were also blinded to the results of the histologic evaluation, which was performed by other pathol-
ogists. Before training, interobserver agreement was evaluated on the training set. After that, two independent 
pathologists were trained via morphologic criteria for DAC and IHC slides of HoxB13 that were matched to 
the H&E-stained slides. The results of HoxB13 IHC performed by the urologic pathologist were blinded to the 
observers. And then, interobserver agreement was evaluated on the training set and the test set after each training.
Statistical analysis. Data were analyzed using SPSS for Windows version 21.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t-test and chi-square test were used for continuous and categorical variables, respectively. Kaplan-Meier 
survival curves and log-rank statistics were employed to evaluate time to tumor metastasis and time to survival. 
Multivariate regression analysis was performed using a Cox proportional hazards model. Statistical significance 
was assumed when P < 0.05.
Spearman’s correlation coefficient was used to evaluate correlation between two diagnostic criteria, and inter-
observer agreement was evaluated by calculating percentage agreement. Cohen’s kappa was used to compare the 
observed agreement and that expected by chance. Kappa values were categorized as previously described33.
Data availability
All data of this study are available from the corresponding author on reasonable request.
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